Results 111 to 120 of about 184,779 (275)

Testing the efficacy of yoga as a complementary therapy for smoking cessation: Design and methods of the BreathEasy trial

, 2014
Beth C. Bock, Rochelle K. Rosen, Joseph L. Fava, Ronnesia B. Gaskins, Ernestine Jennings, Herpreet Thind, James Carmody, Shira Dunsiger, Naama Gidron, Bruce M. Becker, Bess H. Marcus   +10 more
openalex   +2 more sources

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

A comparative analysis of complementary therapies use among patients attending diabetic clinics in Taiwan: 2007 vs. 2023. [PDF]

BMC Complement Med Ther, 2023
Chang HY, Huang YY, Chung CJ, Liu FH.
europepmc   +1 more source

Editorial: Complementary and alternative therapies for sleep disorders: from bench to bedside [PDF]

Jinhuan Yue, Qinhong Zhang, Guo‐qing Zheng, Xiaoqing Zhou, Chi Hao, Hyoung‐Mo Yang, Danqi Zheng, Tiancheng Xu, Brenda Golianu, Guanhu Yang   +9 more
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma. [PDF]

World J Gastrointest Oncol, 2023
Lai HC, Lin HJ, Jeng LB, Huang ST.
europepmc   +1 more source

The use of complementary serological and molecular testing for blood-borne pathogens and evaluation of socio-demographic characteristics of intravenous drug users on substitution therapy from Sumadia district of Serbia

, 2017
Nemanja Borovčanin, Elizabeta Ristanović, Milena Todorović, Milica Borovčanin, Mirjana Jovanović, Bela Balint   +5 more
openalex   +2 more sources

P-91 Do complementary therapies work? [PDF]

, 2017
Sally Baker, Candy Kitz-Atsma, Russ Hargreaves   +2 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

The experience of a program combining two complementary therapies for women with breast cancer: An IPSE qualitative study. [PDF]

PLoS One, 2023
Sibeoni J, Manolios E, Mathé J, Feka V, Vinez MM, Lonsdorfer-Wolf E, Bloch JG, Baylé F, Meunier JP, Revah-Levy A, Verneuil L.   +10 more
europepmc   +1 more source